Skip to content
Palanor is in early release, with our founding customers.Become a founding customer →
PalanorPalanor

Line

Why Industry Clinical Trials Are Stopped

Share of company-led trials terminated over the past 12 months whose stated reason cites each cause, %

Business or funding: 41.9% in Jun 2026+3.4 pp since Jan 2026

Plays the chart through its history. Pauses are where the data set a record or moved most.

Continuation isn't available for Business or funding: Last observation was 144 days ago — too stale to project.

Continuation isn't available for Enrollment: Last observation was 144 days ago — too stale to project.

Continuation isn't available for Safety or efficacy: Last observation was 144 days ago — too stale to project.

ClinicalTrials.gov. Company-led interventional trials that ended, over the 12 months to each month; the newest three months are held back while late reports arrive. Reasons are the sponsor's own words, labelled by fixed word rules; a stop can cite more than one.

Money, patients or the drug itself. When biotech funding tightens or big pharma reshuffles its pipeline, the business line rises; scientific failures show up in the safety-or-efficacy line.

What this chart reads

Sources

Industry Trials Stopped for Business or Funding Reasons (% of Stops). Source: ClinicalTrials.gov (U.S. National Library of Medicine), API v2, refreshed weekly. Palanor counts and classifies the records as described above; it does not change them. ClinicalTrials.gov disclaimer: the U.S. government does not review or approve the safety and science of all studies listed; sponsors and investigators are responsible for their listings.

Industry Trials Stopped for Enrollment Problems (% of Stops). Source: ClinicalTrials.gov (U.S. National Library of Medicine), API v2, refreshed weekly. Palanor counts and classifies the records as described above; it does not change them. ClinicalTrials.gov disclaimer: the U.S. government does not review or approve the safety and science of all studies listed; sponsors and investigators are responsible for their listings.

Industry Trials Stopped for Safety or Efficacy (% of Stops). Source: ClinicalTrials.gov (U.S. National Library of Medicine), API v2, refreshed weekly. Palanor counts and classifies the records as described above; it does not change them. ClinicalTrials.gov disclaimer: the U.S. government does not review or approve the safety and science of all studies listed; sponsors and investigators are responsible for their listings.

Charts are drawn from Palanor's signal library and recomputed from source data on every view. Transformations (changes, indexing, year-on-year rates) are Palanor's.

Related charts

HealthForecast

Drug Stocks Against the Market

Twenty large U.S.-listed drugmakers (by market value) and the S&P 500, price indexed to the start of the window

197.2Data yesterday
HealthForecast

U.S. Uninsured Rate

Share of people in the United States with no health insurance, annual, %

8.2%Data to Dec 2024
HealthForecast

U.S. Drug Overdose Deaths

Drug overdose deaths in the U.S., 12 months ending each month

66,478Data to May 2026
HealthForecast

FDA Novel Drug Approvals

New drugs approved by the FDA’s drug center, trailing 12 months

59Data 51 days ago
Health· StudioForecast

FDA Novel Drug Approvals, Trailing 12 Months

New molecular entities and new therapeutic biologics approved by FDA's Center for Drug Evaluation and Research.

59.0Data 51 days ago
HealthForecast

Donor Aid for Health

Bilateral aid disbursements from DAC member countries by sector, US$ billions, current prices, yearly

$7.3B1 viewsData to Dec 2024

Cookies

We only use essential cookies to keep you signed in and remember your theme. No analytics, no tracking, no ads. See the Privacy Policy for the full read.